New patient treatment in the clinical phase 1 study
The fourth patient has been treated on February 22, 2018 in the Phase 1 study conducted by SpectraCure for the treatment of patients with relapse of prostate cancer. The treatment was performed at Princess Margaret Cancer Centre in Toronto, Canada, and passed without complications and the patient is doing well. The treatment method, called Photodynamic […]
SpectraCure initiates process for change of listing
The Board of SpectraCure AB ("SpectraCure" or the "Company") has decided to initiate a process for change of listing, from AktieTorget to Nasdaq First North Premier. The company's ambition is to implement the list change to Nasdaq First North Premier during 2018. A listing on First North Premier is expected to create favorable conditions for […]
SpectraCure to participate in a large research programme funded by Knut and Alice Wallenberg Foundation
SpectraCure will be an industrial participant in a large research programme in quantum technology, WACQT – Wallenberg Center for Quantum Technology, funded mainly by Knut and Alice Wallenberg Foundation. SpectraCure will receive funding to pay the salary of a researcher at the research school for PhD students covered by the program. The researcher will be […]
Results and strategies of the clinical studies were discussed with the responsible physician
On November 21st SpectraCure arranged a meeting where, among others, Dr. Neil Fleshner participated. Dr. Fleshner is a professor at the division of urology at the University of Toronto and the responsible Uro-oncologist at the Princess Margaret Cancer Centre in Toronto where the first three patients in the company's clinical Phase 1 study were treated. […]
PSA-values from clinical prostate trial mentioned on SpectraCure presentation at ”Stora Aktiedagen” in Stockholm
On November 13, SpectraCure made a company presentation when Aktiespararna arranged “Stora Aktiedagen” at Sheraton Hotel in Stockholm. SpectraCure are currently performing a clinical Phase 1 trial for treatment of patients with recurrent prostate cancer, using the company’s tumour treatment technique photodynamic therapy (PDT). During the presentation, Johannes Swartling, CTO at SpectraCure, mentioned that the […]
SpectraCure presents the company and the progress on their current clinical trial
SpectraCure’s CEO Masoud Khayyami will present the company and the progress on their current clinical trial today, November 13, 2017, at 14:00, at Sheraton Stockholm Hotel. The presentation will be sent live on the internet at www.aktiespararna.se/tv/live. For further information, contact:SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90 SpectraCure in short […]
Imaging material from clinical Phase 1 study
At the PhotonicSweden Workshop on Photonics for Life Science and Regional Innovation Strategies in Kista on October 17th, the CTO of SpectraCure, Johannes Swartling, held a lecture on the company. The company has previously announced that the last treated patient prior to treatment had a PSA value of 4.9 ng/ml and, upon revisiting after treatment, […]
Concept study for next generation product completed
SpectraCure AB has conducted a concept study for the development of the company's technology for the treatment of prostate cancer using photodynamic therapy (PDT). SpectraCures current PDT system, SpectraCure P18 with IDOSE®, has evolved over a ten-year period and is currently used in a Phase 1 clinical trial for the treatment of patients with relapse […]
More preliminary results from the clinical Phase 1 study
SpectraCure is conducting a Phase 1 clinical study for the treatment of patients with relapse in prostate cancer, using the company's photodynamic therapy (PDT) technology. As previously announced, the maximum and final dose of the drug dose product has been reached in the study. During post-treatment follow-up, the PSA value (Prostate-specific antigen) of the patient […]
Positive preliminary results from the clinical Phase 1 study are presented at a scientific conference
SpectraCure is now conducting a Phase 1 clinical study to treat patients with recurring prostate cancer using the company's photodynamic therapy (PDT) technology. As previously announced, the maximum and final dose of the photosensitising drug has been achieved in the study. Magnetic resonance images (MRI) of prostate taken one week after treatment in the patient […]
